Faculty of Medicine, The University of British Columbia, Vancouver, British Columbia, Canada.
Pediatrics, British Columbia Children's Hospital, Vancouver, British Columbia, Canada.
BMJ Open. 2021 Mar 24;11(3):e045010. doi: 10.1136/bmjopen-2020-045010.
Parapneumonic effusion and empyema are common complications of paediatric pneumonia. Acceptable treatment modalities for large parapneumonic effusions include antibiotics alone or in conjunction with surgical interventions. Clear guidelines on the best treatment approach are lacking and mostly based on evidence prior to widespread pneumococcal conjugate 13-valent vaccination (PCV-13).
A living systematic review and network meta-analysis will be performed comparing the five treatment modalities: (1) antibiotics alone; (2) chest tube drainage without fibrinolytics; (3) chest tube drainage with fibrinolytics; (4) video-assisted thoracoscopic surgery and (5) open thoracotomy. The review protocol is reported following the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols guidelines. Eligible studies are randomised controlled trials comparing any pair of interventions in paediatric patients with empyema or parapneumonic effusion. The following databases will be searched: Ovid MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials (CENTRAL), Web of Science, LILACS and Google Scholar. Citation screening and data extraction will be completed using a validated crowdsourcing methodology using InsightScope. To assess the risk of bias, we will use the revised Cochrane risk of bias tool for randomised trials. The primary outcome of the study is the length of stay. Secondary outcomes are (1) periprocedural complications and (2) need for re-intervention. A frequentist network meta-analysis design will be implemented with a random-effects model comparing different interventions. In a subgroup analysis, studies and patients will be stratified by the size of pleural effusion and the date of trial (pre/post-PCV-13). Eligible citations and available results will be uploaded to an online database, hosted on Open Science Framework. The database will be updated at least every 4 months with any newly published research.
No ethics review is required for this study. Results will be published in a peer-reviewed journal. Data will be available as part of an online database summarising the evidence of this living systematic review.
Pending peer review.
小儿肺炎常并发脓胸和胸腔渗出液。对于大量胸腔渗出液,可接受的治疗方法包括单独使用抗生素或联合手术干预。缺乏关于最佳治疗方法的明确指南,且主要基于广泛使用 13 价肺炎球菌结合疫苗(PCV-13)之前的证据。
将对五种治疗方法进行实时系统评价和网络荟萃分析比较:(1)单独使用抗生素;(2)无纤维蛋白溶解剂的胸腔引流管;(3)有纤维蛋白溶解剂的胸腔引流管;(4)电视辅助胸腔镜手术和(5)开胸手术。本综述方案按照系统评价和荟萃分析报告的首选项目(PRISMA)指南进行报告。合格的研究为比较儿童脓胸或胸腔渗出液患者任何两种干预措施的随机对照试验。将检索以下数据库:Ovid MEDLINE、EMBASE、Cochrane 对照试验中心注册库(CENTRAL)、Web of Science、LILACS 和 Google Scholar。使用 InsightScope 验证的众包方法完成引文筛选和数据提取。为评估偏倚风险,我们将使用改良 Cochrane 随机试验偏倚风险工具。研究的主要结局是住院时间。次要结局是(1)围手术期并发症和(2)需要再次干预。将采用随机效应模型的频率主义网络荟萃分析设计比较不同的干预措施。在亚组分析中,将根据胸腔积液量和试验日期(PCV-13 前/后)对研究和患者进行分层。将合格的引文和可用结果上传到一个在线数据库,该数据库托管在开放科学框架上。数据库将至少每 4 个月更新一次,以包含任何新发布的研究。
本研究无需伦理审查。结果将发表在同行评议的期刊上。数据将作为在线数据库的一部分提供,该数据库总结了这项实时系统评价的证据。
PROSPERO 注册:正在等待同行评审。